Data for KEYTRUDA ® (pembrolizumab) Across 16 Types of Cancer from Merck’s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting

Dateline City: KENILWORTH, N.J. Research with KEYTRUDA in Monotherapy and in Combination Includes Findings in Non-Small Cell Lung Cancer (NSCLC), Melanoma, Urothelial Carcinoma, Microsatellite-Instability High (MSI-H) Cancers, Gastric Cancer and Breast Cancer New Overall Survival Data to be Presented in NSCLC, Melanoma and Urothelial CarcinomaKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2 – 6, 2017.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-740-6132orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSE @Merckread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK NYSE: MRK Source Type: news